NEW YORK — AusDiagnostics said on Friday that it has partnered with Acon Laboratories to launch that company's over-the-counter Flowflex COVID-19 Home Test in Australia.
Financial and other terms of the deal were not disclosed.
Acon's Flowflex test is a lateral flow assay designed to detect the SARS-CoV-2 nucleocapsid protein antigen in self-collected anterior nasal swab specimens. San Diego-based Acon received Emergency Use Authorization from the US Food and Drug Administration for the test in October.
The test is also included in the Australian Register of Therapeutic Goods and is being supplied to the UK government's Department of Health and Social Care project of distribution of free lateral flow tests, New South Wales-based AusDiagnostics said.